盐酸头孢唑兰(Cefozopran Hydrochloride) - 药物靶点：PBPs_在研适应症：细菌感染，附件炎，胆管炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Cefozopran、Cefozopran hydrochloride (JP17)

+ [4]

靶点

PBPs

作用机制

PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、细胞壁抑制剂

治疗领域

感染神经系统疾病消化系统疾病+ [6]

在研适应症

细菌感染附件炎胆管炎+ [14]

非在研适应症

（非特异性）化脓性脑膜炎烧伤慢性呼吸道疾病+ [8]

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构

Teva Takeda Yakuhin Ltd.

Takeda Pharmaceutical Co., Ltd.

非在研机构

国药集团致君（深圳）制药有限公司

最高研发阶段批准上市

首次获批日期

日本 (1995-08-01),

附件炎胆管炎胆囊炎+ [13]

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构

分子式C19H18ClN9O5S2

InChIKeyNTJHUKMPVIFDNY-XFDPNJHTSA-N

CAS号113981-44-5

查看全部结构式(2)

关联

3

项与盐酸头孢唑兰相关的临床试验

CTRI/2013/02/003366 / Completed临床3期

Comparative Efficacy, Safety and Tolerability of Inj. Cefozopran Hydrochloride and Inj. Cefpirome Sulphate in the Treatment of Community Acquired Pneumonia - An Open-label Study.

开始日期2013-02-25

申办/合作机构

Ranbaxy Laboratories Ltd.

CTRI/2013/02/003340 / Completed临床3期

Comparative Efficacy, Safety and Tolerability of Inj. Cefozopran Hydrochloride and Inj. Cefpirome Sulphate in the Treatment of Complicated Urinary Tract Infections and Pyelonephritis - An Open-label Study.

开始日期2013-02-04

申办/合作机构

Ranbaxy Laboratories Ltd.

CTR20140358 / Completed临床1期

注射用盐酸头孢唑兰人体药代动力学研究

对健康受试者进行注射用盐酸头孢唑兰的药代动力学试验，测定头孢唑兰的经时血药浓度，计算头孢唑兰药代动力学参数，了解注射用盐酸头孢唑兰在人体吸收、分布、代谢、消除规律，为制定注射用盐酸头孢唑兰II期临床试验方案提供试验依据。

开始日期2009-09-14

申办/合作机构

国药集团致君（深圳）制药有限公司

100 项与盐酸头孢唑兰相关的临床结果

登录后查看更多信息

100 项与盐酸头孢唑兰相关的转化医学

登录后查看更多信息

100 项与盐酸头孢唑兰相关的专利（医药）

登录后查看更多信息

184

项与盐酸头孢唑兰相关的文献（医药）

2024-09-02·Current Topics in Medicinal Chemistry

Recent Advances in Nanocatalyzed One-Pot Sustainable Synthesis of Bioactive N, N-Heterocycles with Anticancer Activities: An Outlook of Medicinal Chemistry

Article

作者: Majhi, Sasadhar

N-heterocycles represent a predominant and unique class of organic chemistry. They have received a lot of attention due to their important chemical, biomedical, and industrial uses. Food and Drug Administration (FDA) approved about 75% of drugs containing N-based heterocycles, which are currently available in the market. N-Heterocyclic compounds exist as the backbone of numerous natural products and act as crucial intermediates for the construction of pharmaceuticals, veterinary items, and agrochemicals frequently. Among N-based heterocyclic compounds, bioactive N,N-heterocycles constitute a broad spectrum of applications in modern drug discovery and development processes. Cefozopran (antibiotic), omeprazole (antiulcer), enviradine (antiviral), liarozole (anticancer), etc., are important drugs containing N,N-heterocycles. The synthesis of N,Nheterocyclic compounds under sustainable conditions is one of the most active fields because of their significant physiological and biological properties as well as synthetic utility. Current research is demanding the development of greener, cheaper, and milder protocols for the synthesis of N,N-heterocyclic compounds to save mother nature by avoiding toxic metal catalysts, extensive application of energy, and the excessive use of hazardous materials. Nanocatalysts play a profound role in sustainable synthesis because of their larger surface area, tiny size, and minimum energy; they are eco-friendly and safe, and they provide higher yields with selectivity in comparison to conventional catalysts. It is increasingly demanding research to design and synthesize novel bioactive compounds that may help to combat cancer since the major causes of death worldwide are due to cancer. Hence, the important uses of nanocatalysts for the one-pot synthesis of biologically potent N,N-heterocycles with anticancer activities have been presented in this review.

2024-07-01·Journal of Infection and Chemotherapy

Analysis of bacteremia at first-line antibiotic treatment for febrile neutropenia in children and adolescents: A retrospective, single-center analysis

Article

作者: Sano, Hirozumi ; Kobayashi, Ryoji ; Matsushima, Satoru ; Hori, Daiki ; Suzuki, Daisuke ; Yanagi, Masato

BACKGROUNDControl of bacterial and fungal infections is critical to improving outcomes in hematological neoplastic diseases of children and adolescents. In this study, a retrospective analysis of our previous studies on febrile neutropenia was performed to investigate bacteremia.PROCEDUREFrom August 2008 to December 2023, five antibiotic studies were performed for febrile and neutropenic pediatric patients who had been treated with chemotherapy, immunosuppressive therapy, or had received stem cell transplantation in the pediatric unit at Sapporo Hokuyu Hospital. The rate of positive blood culture, detected bacteria, and susceptibility of several types of antibiotics in febrile episodes were investigated.RESULTSBlood culture was positive in 133 of 1604 febrile episodes of 329 patients. Detected bacteria were Gram-positive cocci (61.2 %), Gram-negative bacilli (27.6 %), Gram-negative cocci (0.7 %), and Gram-positive bacilli (10.4 %). The incidence of bacteremia over time showed a decreasing trend with each passing year. In particular, the incidence of bacteremia was around 10 % in 2008-2013, whereas it was often below 5 % after 2020; this decrease was statistically significant. Although almost all detected bacteria and their susceptibilities to antibiotics (piperacillin/tazobactam, meropenem, ceftazidime, and cefozopran) did not change over time, all Escherichia coli detected after 2014 were extended-spectrum β-lactamase-producing bacteria.

2024-05-01·Journal of Infection and Chemotherapy

Blood culture bottles for culturing cerebrospinal fluid in cases of bacterial meningitis caused by Enterococcus faecalis: A case report

作者: Taguchi, Akira ; Kitagawa, Hiroki ; Nomura, Toshihito ; Kinoshita, Yasuyuki ; Koba, Yumiko ; Hattori, Noboru ; Ohge, Hiroki ; Inada, Shugo ; Omori, Keitaro ; Shigemoto, Norifumi

Pathogen identification is essential for the treatment of bacterial meningitis. However, cerebrospinal fluid (CSF) culture tests are often negative when antimicrobial agents are administered before CSF is collected. Therefore, it is necessary to improve the culturing process for such samples. Here, we report a case of bacterial meningitis where the causative bacteria were detected by inoculating that patient's CSF samples into blood culture bottles. A 52-year-old man developed a fever and headache after undergoing transnasal transsphenoidal surgery for a nonfunctioning pituitary neuroendocrine tumor. He was suspected of having a wound infection, for which he was treated with cefozopran and vancomycin. A CSF test was also performed, owing to persistent fever, and bacterial meningitis was suspected. Although conventional CSF culture tests were negative, CSF cultures using blood culture bottles detected Enterococcus faecalis. The antimicrobial agents were therefore changed to ampicillin and gentamicin, after which the patient's meningitis improved. The blood culture bottles used contained adsorbed polymer beads with antimicrobial neutralizing properties, which likely contributed to the isolation of the bacteria. In addition to conventional cultures, ones done in blood culture bottles may be useful for diagnosing bacterial meningitis via CSF samples-particularly in cases where antimicrobial agents have already been administered.

100 项与盐酸头孢唑兰相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02233	盐酸头孢唑兰	J01DE03	DB13667

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
细菌感染	日本	Takeda Pharmaceutical Co., Ltd.	1995-10-20
附件炎	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
胆管炎	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
胆囊炎	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
膀胱炎	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
脓胸	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
出血性败血症	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
角膜炎	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
喉炎	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
肝脓肿	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
肺脓肿	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
脑膜炎	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
腹膜炎	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
肺炎	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
肾盂肾炎	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
继发感染	日本	Teva Takeda Yakuhin Ltd.	1995-08-01
扁桃体炎	日本	Teva Takeda Yakuhin Ltd.	1995-08-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脓胸	临床2期	中国	国药集团致君（深圳）制药有限公司	2009-09-14
眼内炎	临床2期	中国	国药集团致君（深圳）制药有限公司	2009-09-14
喉炎	临床2期	中国	国药集团致君（深圳）制药有限公司	2009-09-14
肺脓肿	临床2期	中国	国药集团致君（深圳）制药有限公司	2009-09-14
眼眶感染	临床2期	中国	国药集团致君（深圳）制药有限公司	2009-09-14
鼻旁窦疾病	临床2期	中国	国药集团致君（深圳）制药有限公司	2009-09-14
腹膜炎	临床2期	中国	国药集团致君（深圳）制药有限公司	2009-09-14
前列腺炎	临床2期	中国	国药集团致君（深圳）制药有限公司	2009-09-14
肾盂肾炎	临床2期	中国	国药集团致君（深圳）制药有限公司	2009-09-14
涎腺炎	临床2期	中国	国药集团致君（深圳）制药有限公司	2009-09-14